Stock of the Day

January 26, 2021

Denali Therapeutics (DNLI)

$23.83
+$0.93 (+4.1%)
Market Cap: $3.78B

About Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Today's Trend

Denali Therapeutics Inc. (NASDAQ: DNLI) appears to be getting a modest lift from a cluster of bullish analyst updates, especially HC Wainwright’s reiterated Buy rating and $42 price target.

  • HC Wainwright reiterated a Buy rating on Denali Therapeutics and maintained a $42 price target, signaling continued confidence in the company’s longer-term pipeline and valuation potential.
  • The firm also raised earnings estimates across multiple periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, FY2029, and FY2030, which can support investor sentiment if the market views the revisions as evidence of improving outlook.
  • Denali also presented at the Bank of America Global Healthcare Conference 2026, which may have helped keep attention on the stock by giving investors an update on the company’s strategy and development pipeline. Article Title
  • BTIG Research also reportedly initiated or maintained a Buy view on DNLI, adding to the generally constructive analyst backdrop. Article Title
  • Despite the upbeat ratings, Denali remains unprofitable, with analysts still expecting negative EPS across the next several years, which may limit upside if investors focus on cash burn and commercialization risk.

Overall, DNLI’s stock is moving higher on analyst optimism, with Wall Street highlighting improving earnings estimates and a favorable long-term outlook, even though the company is still expected to post losses.

← Previous Stock of the DayNext Stock of the Day →